Baseline characteristics

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) · Source last updated 2025-11-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      47

   units

   Participants

groups

1. description

   Pemigatinib 13.5 milligrams (mg) was self-administered once daily (QD) as oral tablets on an intermittent dosing (ID) schedule or continuous dosing (CD) schedule. Participants started pemigatinib 13.5 mg on the ID schedule (i.e., 2 weeks on/1 week off) as per the initial Protocol and on the CD schedule in 21-day cycles following a Protocol amendment.

   id

   BG000

   title

   Pemigatinib 13.5 mg

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            spread

            13.25

            value

            58.3

   dispersion Type

   STANDARD_DEVIATION

   param Type

   MEAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            25

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            22

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            30

         title

         White

      2. measurements

         1. group Id

            BG000

            value

            4

         title

         Black or African American

      3. measurements

         1. group Id

            BG000

            value

            4

         title

         Asian

      4. measurements

         1. group Id

            BG000

            value

            5

         title

         Missing

      5. measurements

         1. group Id

            BG000

            value

            2

         title

         Not Provided

      6. measurements

         1. group Id

            BG000

            value

            1

         title

         White/Caucasian and American-Indian Alaska Native

      7. measurements

         1. group Id

            BG000

            value

            1

         title

         African

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Race/Ethnicity, Customized

   unit Of Measure

   Participants

4. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            1

         title

         Hispanic or Latino

      2. measurements

         1. group Id

            BG000

            value

            33

         title

         Not Hispanic or Latino

      3. measurements

         1. group Id

            BG000

            value

            8

         title

         Not Reported

      4. measurements

         1. group Id

            BG000

            value

            1

         title

         Unknown

      5. measurements

         1. group Id

            BG000

            value

            4

         title

         Captured as "Other" in Database

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Race/Ethnicity, Customized

   unit Of Measure

   Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice